Matrix metalloproteinases during and outside of migraine attacks without aura

M Ashina1, J F Tvedskov, K Lipka

  • 1Department of Neurology, Glostrup Hospital, Danish Headache Centre, Copenhagen, Denmark. ashina@dadlnet.dk

Insights

Migraine attacks did not alter matrix metalloproteinase-9 (MMP-9) levels, suggesting MMP-9 is not a biomarker for blood-brain barrier (BBB) disruption. Unexpectedly, MMP-3 levels decreased during migraine attacks.

Area of Science:

  • Neuroscience
  • Biochemistry

Background:

  • Migraine pathophysiology is complex, with potential involvement of blood-brain barrier (BBB) disruption.
  • Matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) are implicated in tissue remodeling and may influence BBB permeability.

Purpose of the Study:

  • To investigate the role of MMPs and TIMPs in BBB alterations during migraine attacks.
  • To determine if MMP-9 can serve as a biomarker for BBB disruption in migraine without aura.

Main Methods:

  • Plasma levels of MMP-3, MMP-9, TIMP-1, MMP-7, MMP-8, MMP-10, and TIMP-2 were measured in 21 migraine patients during and outside of attacks.
  • Multi-analyte profiling and protein array technologies were utilized.

Main Results:

  • No significant differences were observed in MMP-9 and TIMP-1 levels between ictal and interictal periods.
  • Significantly decreased plasma levels of MMP-3 were found in both external jugular and cubital veins during migraine attacks.
  • No correlation was found between MMP levels and migraine duration or frequency.

Conclusions:

  • Plasma MMP-9 is not a reliable biomarker for BBB disruption in migraine without aura.
  • The observed decrease in MMP-3 levels during migraine attacks is an unexpected finding that requires further research.